Royalty Pharma’s $728 Million Secondary Offering

Davis Polk advised Royalty Pharma plc and the selling shareholders on the offering.

Royalty Pharma executed its $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling shareholders. The Class A ordinary shares are listed on the Nasdaq Global Select Market under the symbol “RPRX.”

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. (Picture), counsel Jeffrey S. Ramsay and associates Jacqueline Marino and Daniel Chao. Partner Simon Witty, counsel Simon J. Little and associate Marcelo Valenca provided English law advice. The executive compensation team included counsel Gregory D. Hughes. Partners Michael Mollerus and Jonathan Cooklin provided U.S. and English tax advice. Partner David R. Bauer provided intellectual property advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Daniel Chao – Davis Polk & Wardwell; Jonathan Cooklin – Davis Polk & Wardwell; Gregory Hughes – Davis Polk & Wardwell; Simon Little – Davis Polk & Wardwell; Jacqueline Marino – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Jeffrey Ramsay – Davis Polk & Wardwell; Richard Truesdell Jr. – Davis Polk & Wardwell; Marcelo Valenca – Davis Polk & Wardwell; Simon Witty – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Royalty Pharma;

Author: Ambrogio Visconti